Patent ID: 11890304
Assignee: JANSSEN BIOTECH, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method for generating human pancreatic endocrine cells, comprising:
differentiating human pluripotent stem cells into definitive endoderm cells by culturing the pluripotent cells in a medium supplemented with activin A, then removing the medium supplemented with activin A;
differentiating the definitive endoderm cells into pancreatic endoderm cells by culturing the definitive endoderm cells in a medium supplemented with retinoic acid and fibroblast growth factor-2 (FGF-2), then removing the medium supplemented with retinoic acid and FGF-2; and
differentiating the pancreatic endoderm cells into pancreatic endocrine cells by culturing the pancreatic endoderm cells in a medium supplemented with 1S-Benzyl-4R41-(1S-carbamoyl-2-phenethylcarbamoyl)-1S-3-methylbutylcarbamoyl]-2R-hydrozy-5-phenylpentyl] carbamic Acid tert-butyl Ester (L-685,458), thereby generating the pancreatic endocrine cells, wherein FGF-2 is used at a concentration of about 20 ng/ml to about 50 ng/ml.